Is tenofovir/emtricitabine teratogenic?
- PMID: 25083255
- PMCID: PMC4110866
- DOI: 10.1177/2042098613485276
Is tenofovir/emtricitabine teratogenic?
Abstract
The Truvada(®) (tenofovir/emtricitabine) and nevirapine combination is increasingly being prescribed for prevention of mother-to-child HIV transmission. There is presently no documented evidence of teratogenicity of either tenofovir/emtricitabine or nevirapine. We report two cases of spina bifida in infants of mothers on this drug combination.
Keywords: emtricitabine; nevirapine; pregnancy; spina bifida; tenofovir; teratogenicity.
Conflict of interest statement
References
-
- Antiretroviral Pregnancy Registry (2012) Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 January 2012. Wilmington, NC: Registry Co-ordinating Centre. http://www.apregistry.com (accessed 10 January 2013).
-
- Audu L., Shehu B., Thom-Manuel I., Mairami A.(2004) Open neural tube defects at the National Hospital, Abuja: an analysis of clinical patterns and neonatal outcome. Niger J Paediatr 31: 131–136
-
- Federal Ministry of Health (2010) Prevention of Mother-to-child Transmission of HIV (PMTCT). http://nascp.gov.ng (accessed 11 January 2013).
LinkOut - more resources
Full Text Sources
Other Literature Sources